Yposkesi joins BioPhorum CGT consortium

Published: 24-Aug-2021

Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a rapidly evolving regulatory environment

Yposkesi, a CDMO for companies developing cell and gene therapies, has announces its membership of BioPhorum, CGT Phorum. The organisation is a global consortium bringing together biopharmaceutical manufacturers and suppliers to collaborate on mutual challenges in the industry.

Biologics manufacture is highly complex. Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency, while operating in a rapidly evolving regulatory environment, as well as responding to market pressures for commercialising cell and gene therapies within shorter timeframes.

“Given the burgeoning state of bioprocessing for cell and gene therapies, many companies, including Yposkesi, are confronting the same issues. Yet we are working on them in isolation. It makes more sense to work together to solve these problems in a more time-efficient and consistent way,” said Brian Mullan, Head of Innovation, Analytical and Process Development at Yposkesi. “BioPhorum has a well-established reputation as a collaborative, proactive and productive forum to develop solutions to common problems in the bioprocessing sector. As a new member, we look forward to engaging in collaborations to achieve this objective.”

Membership of the consortium covers access to, and participation in, various workstreams and teams focused on different concepts important to the industry, including process validation, analytics and regulation.

Besides its expertise in developing adeno-associated virus (AAV) and lentiviral vector (LV) manufacturing platforms, the company will bring to BioPhorum its experience in applying these to projects for its global clients. It will also be able to offer its expertise in CGT technical development and manufacturing.

“BioPhorum is delighted to welcome Yposkesi as a member of the Cell & Gene Therapy Phorum,” said Louis Bennett, CGT Phorum lead. “We look forward to collaborating with its experts on the key CGT industry priorities. The expertise in AAV and Lentiviral methodologies that Yposkesi brings will enhance the discussions across the member companies and support development of innovative approaches to support the industry.”

You may also like